Related Experiment Video
Updated: Jul 14, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
The role of TNFalpha in ulcerative colitis
Bruce E Sands1, Gilaad G Kaplan
1Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Diseases, and MGH Crohn's and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. bsands@partners.org
Standard ulcerative colitis treatments often fail, necessitating colectomy for 20-30% of patients. Targeting tumor necrosis factor alpha (TNFalpha) with biologic therapies shows promise for treating this inflammatory bowel disease effectively.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Standard ulcerative colitis (UC) care includes pharmacotherapy and colectomy.
- 20-30% of UC patients require colectomy due to treatment non-response or intolerance.
- Cytokines, particularly tumor necrosis factor alpha (TNFalpha), are key in UC inflammation.
Purpose of the Study:
- To review the role of TNFalpha in ulcerative colitis pathogenesis.
- To evaluate the efficacy of anti-TNFalpha therapies in ulcerative colitis treatment.
Main Methods:
- Review of recent randomized controlled trials (RCTs) on biologic anti-TNFalpha therapy.
- Analysis of studies investigating TNFalpha's genetic association and levels in UC patients.
Main Results:
- Biologic anti-TNFalpha therapy has been confirmed as effective in recent RCTs for UC.
- Increased TNFalpha levels and genetic associations support its role in UC pathogenesis.
Conclusions:
- TNFalpha is a critical factor in ulcerative colitis pathophysiology.
- Targeting TNFalpha with biologic agents represents a promising therapeutic strategy for UC.
- Further investigation into soluble TNFalpha receptors and agents inhibiting TNFalpha production is warranted.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

